Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.09
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.09
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.46
Previous CloseN/A
Volume4.23M
Average Volume (3M)877.83K
Market Cap
AU$41.63M
Enterprise ValueAU$97.38
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Sep 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding489,719,850
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$2.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetA low debt-to-equity ratio indicates limited financial leverage and lower fixed interest obligations, reducing near-term solvency risk. For a clinical-stage biopharma this conservatism preserves flexibility to finance trials or pursue partnerships without heavy interest burdens.
High Gross Profit Margin PotentialA reported 100% gross profit margin (despite current revenue weakness) suggests that any future commercialized therapies could convert sales to gross profit efficiently. High gross margins support operating leverage, enabling scalability and attractive economics for partnering or licensing.
Diversified Immuno-oncology PipelineA multi-modality pipeline (oncolytic viruses, B‑cell activating therapies and CAR T approaches) provides multiple development pathways and reduces binary program risk. Structural diversification improves chances of a value-inflecting outcome and enhances partnering/licensing appeal.
Bears Say
Steep Revenue DeclineA very large year-over-year revenue decline signals absence of meaningful recurring commercial sales and weak operating scale. For a development-stage biotech this heightens reliance on financing and creates execution risk: failing to convert R&D into sustained revenue undermines long-term viability.
Weak Operating Cash GenerationNegative operating cash flows indicate the business burns cash in core operations, forcing dependency on external funding. Over several months this structural cash gap raises dilution risk from equity raises and constrains the company’s ability to progress multiple clinical programs simultaneously.
Negative Return On EquityA deeply negative ROE reflects persistent capital destruction and inability to generate returns from invested equity. This structural weakness hampers investor confidence and reduces attractiveness to strategic partners who seek efficient capital deployment and demonstrable value creation.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.08 and its highest was AU$0.46 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$41.63M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Undervalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.04.
How many shares outstanding does Imugene have?
Imugene has 489,719,850 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (177.78% Upside)
AU$0.25 (177.78% Upside)
Blogger Sentiment
Bullish
AU:IMU Sentiment 62%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$79.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
IMU Stock 12 Month Forecast
Average Price Target
AU$0.25
▲(177.78% Upside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―